NCT02654938 - Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Prostate Cancer

Interventions

DRUG

Mobilan (M-VM3)

Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.

DRUG

Placebo

5% infusion solution of dextrose

Trial Locations (6)

Unknown

"Federal State Budgetary Institution Russian Oncological Research Center named after N. N. Blokhin of the Russian Academy of Sciences", Moscow

Moscow Scientific Research Institute of Oncology named after P. A. Hertsen of the Ministry of Health of the Russian Federation, Moscow

"Moscow State Budgetary Healthcare Institution City Clinical Hospital № 57 of Moscow Healthcare Department", Moscow

Moscow State University of Medicine and Dentistry, Moscow

"Federal State Budgetary Institution Saint Petersburg Clinical Scientific and Practical Center for Special types of medical care (Oncological)", Saint Petersburg

"Federal State Budgetary Institution Scientific Research Oncology Institute named after N.N. Petrov of the Ministry of Health of the Russian Federation", Saint Petersburg